Puma Biotechnology Inc. buy WatchMen
Start price
26.03.24
/
50%
€5.30
Target price
26.03.25
€10.00
Performance (%)
-15.43%
Price
09.05.24
€4.48
Summary
This prediction is currently active. The price of Puma Biotechnology Inc. has decreased since the start of the prediction. Compared to the start price this results in a performance of -15.43%. This prediction currently runs until 26.03.25. The prediction end date can be changed by WatchMen at any time. WatchMen has 50% into this predictionPuma Biotechnology is a publicly traded biopharmaceutical company that develops innovative cancer therapies targeting the most aggressive and difficult-to-treat forms of the disease. Puma's lead product is Nerlynx, an oral medication approved for the treatment of HER2-positive breast cancer, and the company also has a number of other promising drugs in its pipeline. Founded in 2010, Puma is headquartered in Los Angeles, California, and its shares trade on the NASDAQ exchange under the ticker symbol PBYI.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Puma Biotechnology Inc. | -1.364% | -1.364% |
| iShares Core DAX® | 4.015% | 2.971% |
| iShares Nasdaq 100 | 2.755% | 0.503% |
| iShares Nikkei 225® | -0.826% | -5.057% |
| iShares S&P 500 | 2.330% | 0.720% |
Comments by WatchMen for this prediction
In the thread Puma Biotechnology Inc. diskutieren
Buy Puma Biotechnology Inc.